SAN DIEGO, CA / ACCESS Newswire / December 8, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, announces the launch of IBD Precis ™, a next-generation ...
Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, the companies said Sunday, in a deal intended to bolster the buyer’s immunology drug pipeline as it faces loss of ...
- PRA052 is the second clinical candidate identified using the Prometheus360™ platform with one of the strongest genetic associations to IBD and is linked to a broad range of immune-mediated diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback